Physician profile
Aimaz Afrough
NPI 1477964518
$16,850.40
in general payments reported to CMS, 2019-2025
27 companies · $2,969 in 2025
The $2,969 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,087 · 2020: $215 · 2021: $8.25 · 2022: $450 · 2023: $322 · 2024: $12K · 2025: $2,969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $2,348 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,200 · Travel and Lodging: $21.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,519.25 |
| Food and Beverage | $2,347.96 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,200.00 |
| Travel and Lodging | $21.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $4,400.90 | 2022-2025 | Tecvayli, Talvey, Darzalex |
| Genzyme Corporation | $3,760.17 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,657.53 | 2019-2024 | |
| Pfizer INC. | $2,404.57 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $1,802.34 | 2022-2025 | Tecvayli, Talvey, Carvykti |
| Celgene Corporation | $331.79 | 2019-2023 | |
| Karyopharm Therapeutics INC. | $220.69 | 2025 | Xpovio |
| Sanofi-Aventis U.S. LLC | $173.69 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $141.16 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $132.91 | 2019 | |
| Beigene USA, INC. | $125.00 | 2022 | |
| Lilly USA, LLC | $114.70 | 2019-2020 | |
| Legend Biotech USA INC. | $103.57 | 2024 | |
| Astrazeneca Uk Limited | $96.21 | 2025 | Calquence |
| Incyte Corporation | $66.14 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $56.27 | 2025 | Clonoseq |
| Jazz Pharmaceuticals INC. | $49.47 | 2019 | |
| Agios Pharmaceuticals, INC. | $45.34 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $36.52 | 2023 | |
| Daiichi Sankyo INC. | $30.93 | 2020 | |
| Tempus Ai, INC | $29.34 | 2025 | Xt Cdx |
| Rigel Pharmaceuticals, INC. | $24.22 | 2020 | |
| Astellas Pharma US INC | $21.69 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.00 | 2019 | |
| Eurofins Viracor, LLC | $8.25 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimaz Afrough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.